Long-term survival on hemodialysis | 15–25 years is possible
Long-term survival on hemodialysis:
15–25 years is possible – evidence from 13 patients
Common misconception: “Dialysis patients live only 5 years and their life is miserable.”
Truth: Average survival is 5–10 years, but that is an average across all ages and illnesses. Many patients live 15, 20, or even 25+ years with good quality of life – especially when they start younger, have no diabetes, and actively participate in their care.
✅ Our key message: Long dialysis survival depends more on patient behavior, underlying cause, and adherence than on dialysis itself. Life expectancy on dialysis is not fixed – it is shaped by choices, support, and medical factors.
Our patient cohort – 13 patients on dialysis for >15 years
We analyzed retrospective data from our hemodialysis center. All patients below have been on dialysis for at least 15 years. Several have exceeded 20 years, with a maximum of 25 years on renal replacement therapy (dialysis or transplant).
Baseline characteristics
| Characteristic | Our cohort (n=13) |
|---|
| Male : Female | 9 : 4 |
| Age at starting dialysis (average) | 30 years (youngest 12, oldest 48) |
| Primary cause of ESKD | Glomerulonephritis (9), Alport syndrome (2), Polycystic kidney disease (1), Neurogenic bladder (1) |
| Diabetic nephropathy | 0 (no diabetes type 1 or type 2) |
| Pre-renal causes (heart failure, severe atherosclerosis) | 0 |
| Hypertension at dialysis start | 13 (all well-controlled with dialysis + medications) |
| Blood transfusion history | 0 (except one patient with a single episode) |
| Hospitalization days (over entire dialysis history) | 0–1 hospitalization per patient (very low) |
| Skipping dialysis sessions | 0 (none skipped any session) |
| Urgent (unplanned) dialysis start | Only 1 patient |
| Medication commitment | High (all took binders, BP meds, etc. as prescribed) |
| Itching (pruritus) | 0 (none reported significant itching) |
| Average intradialytic weight gain | 3 kg (range 2–4 kg, controlled) |
| Education level | Elementary (9), College (2), University (2) |
Bone metabolism (PTH levels)
| PTH category | Number of patients |
|---|
| <150 pg/mL (low) | 5 |
| 150–1000 pg/mL (target range) | 3 |
| >1000 pg/mL (high) | 5 |
→ Despite wide variation in PTH (both low and high bone disease), all patients survived >15 years with appropriate management.
Dialysis duration in this group
- Maximum: 25 years
- Minimum: 15.3 years
- Average: 20 years
⚠️ Important limitation – please read:
Our cohort is younger (average starting age 30) and excludes diabetes. In the general dialysis population, the average starting age is ~65 years, and many have diabetes and heart disease. Therefore, these results cannot be directly applied to every patient. However, the principles we identified – no skipped sessions, medication adherence, controlled fluid gain, low hospitalizations – improve survival for all dialysis patients, regardless of age.
What helped these patients survive >15 years?
From our analysis, the following factors were consistently present in long-term survivors:
- No diabetes mellitus – diabetes accelerates vascular disease, infection risk, and access failure.
- Never missed a dialysis session – 100% adherence over decades.
- Low hospitalization rate and no blood transfusions – associated with lower chronic inflammation.
- Stable intradialytic weight gain (≈3 kg) – avoids fluid overload and heart strain.
- High medication adherence – phosphate binders, antihypertensives, and vitamin D analogs taken regularly.
- Good adaptation and understanding of their disease – minimal denial, active partnership with healthcare team.
- Social support (especially family) – not formally measured in our table, but clinically evident in every case.
What did NOT prevent long survival?
- Low education level – most patients had only elementary education, but family and routine compensated.
- Wide PTH range – metabolic bone disease was managed, not absent.
- Temporary catheters early on – all eventually received a functioning arteriovenous fistula.
Why does this matter? The role of inflammation
Chronic kidney disease (CKD) is now understood as a state of persistent, low-grade inflammation. Inflammation drives cardiovascular disease, malnutrition, and faster decline. In our long-surviving patients, we observed:
- No recurrent infections
- No blood transfusions (which trigger inflammatory responses)
- No skipped sessions (which cause uremic flares)
- Stable fluid status
We hypothesize that these factors reduced inflammasome activation and gut dysbiosis, although further research is needed. The emerging field of proteomics and biomarkers may one day help predict which patients will achieve long-term survival.
Practical take-home message for patients and families
If you start dialysis at a younger age (under 50), have no diabetes, attend every session, take your medications consistently, control your fluid gain, and have family support – then 15+ years on dialysis is a realistic goal, not a miracle.
Even if you are older or have diabetes, improving adherence and avoiding skipped sessions will meaningfully extend your life and improve its quality.
Final conclusion
The concept that “dialysis = short, miserable life” is a harmful generalization. It applies to some patients, but it is far from inevitable. Life expectancy on dialysis depends on a combination of:
- Age and cause of kidney disease
- Presence of diabetes and vascular disease
- Behavioral factors (skipping sessions, medication adherence, fluid control)
- Social support and psychological adaptation
Our 13 patients prove that two decades on dialysis is possible with good quality of life. We hope their example encourages both patients and healthcare providers to aim higher.